Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 16/20 | 0.80 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | MMP14 | P50281 | 4/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23354223 | 1.00 | ADAMTS7 (0.80) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL23371320 | 0.90 | ADAMTS7 (0.77) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL23353983 | 0.89 | ADAMTS7 (1.00) | ADAMTS7ADAMTS4ADAMTS5ADAM17 | |
| SCHEMBL29979132 | 0.89 | ADAMTS7 (1.00) | ADAMTS7ADAMTS4ADAMTS5ADAM17 | |
| SCHEMBL23367129 | 0.89 | ADAMTS7 (0.76) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL24928052 | 0.88 | ADAMTS7 (0.63) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL23367131 | 0.88 | ADAMTS7 (0.65) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL23354021 | 0.88 | ADAMTS7 (0.65) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL29978905 | 0.88 | ADAMTS7 (0.65) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL24927956 | 0.85 | ADAMTS7 (0.82) | ADAMTS7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | ADAMTS7 1/4885ADAMTS4 6/4885MMP2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.